Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease

Drug-resistant mutations often have deleterious impacts on replication fitness, posing a fitness cost that can only be overcome by compensatory mutations. However, the role of fitness cost in the evolution of drug resistance has often been overlooked in clinical studies or in vitro selection experiments, as these observations only capture the outcome of drug selection. In this study, we systematically profile the fitness landscape of resistance-associated sites in HIV-1 protease using deep mutational scanning. We construct a mutant library covering combinations of mutations at 11 sites in HIV-1 protease, all of which are associated with resistance to protease inhibitors in clinic. Using deep sequencing, we quantify the fitness of thousands of HIV-1 protease mutants after multiple cycles of replication in human T cells. Although the majority of resistance-associated mutations have deleterious effects on viral replication, we find that epistasis among resistance-associated mutations is predominantly positive. Furthermore, our fitness data are consistent with genetic interactions inferred directly from HIV sequence data of patients. Fitness valleys formed by strong positive epistasis reduce the likelihood of reversal of drug resistance mutations. Overall, our results support the view that strong compensatory effects are involved in the emergence of clinically observed resistance mutations and provide insights to understanding fitness barriers in the evolution and reversion of drug resistance.

[1]  R. Levy,et al.  Epistasis and entrenchment of drug resistance in HIV-1 subtype B , 2019, eLife.

[2]  C. Schiffer,et al.  Constrained mutational sampling of amino acids in HIV-1 protease evolution , 2018, bioRxiv.

[3]  Matthew R. McKay,et al.  Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies , 2018, Proceedings of the National Academy of Sciences.

[4]  R. Detels,et al.  Effects of Mutations on Replicative Fitness and Major Histocompatibility Complex Class I Binding Affinity Are Among the Determinants Underlying Cytotoxic-T-Lymphocyte Escape of HIV-1 Gag Epitopes , 2017, mBio.

[5]  M. Wainberg,et al.  Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. , 2017, Virus research.

[6]  R. Levy,et al.  Potts Hamiltonian models of protein co-variation, free energy landscapes, and evolutionary fitness. , 2017, Current opinion in structural biology.

[7]  Martin Weigt,et al.  Large-scale identification of coevolution signals across homo-oligomeric protein interfaces by direct coupling analysis , 2017, Proceedings of the National Academy of Sciences.

[8]  Ryan D. Hernandez,et al.  Functional Segregation of Overlapping Genes in HIV , 2016, Cell.

[9]  J. Mugisha,et al.  Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains , 2016, Theoretical population biology.

[10]  R. Sun,et al.  Quantifying the evolutionary potential and constraints of a drug-targeted viral protein , 2016 .

[11]  R. Levy,et al.  Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease , 2016, bioRxiv.

[12]  Tyler N. Starr,et al.  Epistasis in protein evolution , 2016, Protein science : a publication of the Protein Society.

[13]  J. O'Neill,et al.  Tackling drug-resistant infections globally: final report and recommendations , 2016 .

[14]  Dmitry Chudakov,et al.  Local fitness landscape of the green fluorescent protein , 2016, Nature.

[15]  B. Walker,et al.  Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable , 2016, Nature Communications.

[16]  James O Lloyd-Smith,et al.  Adaptation in protein fitness landscapes is facilitated by indirect paths , 2016, bioRxiv.

[17]  Simona Cocco,et al.  ACE: adaptive cluster expansion for maximum entropy graphical model inference , 2016, bioRxiv.

[18]  Tara L. Kieffer,et al.  Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.

[19]  R. Sanjuán,et al.  Extremely High Mutation Rate of HIV-1 In Vivo , 2015, PLoS biology.

[20]  A. Chakraborty,et al.  Identification of drug resistance mutations in HIV from constraints on natural evolution. , 2015, Physical review. E.

[21]  L. James,et al.  HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry , 2015, Journal of Virology.

[22]  Yuan Chu,et al.  HIV protease inhibitors: a review of molecular selectivity and toxicity , 2015, HIV/AIDS.

[23]  Zhiqiang Tan,et al.  Deep Sequencing of Protease Inhibitor Resistant HIV Patient Isolates Reveals Patterns of Correlated Mutations in Gag and Protease , 2015, PLoS Comput. Biol..

[24]  Huldrych F. Günthard,et al.  Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds , 2015, PLoS pathogens.

[25]  Jun Lin,et al.  Mechanisms of antibiotic resistance , 2015, Front. Microbiol..

[26]  R. Sun,et al.  High-throughput profiling of point mutations across the HIV-1 genome , 2014, Retrovirology.

[27]  M. Webber,et al.  Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.

[28]  Nicholas C. Wu,et al.  A Comprehensive Biophysical Description of Pairwise Epistasis throughout an Entire Protein Domain , 2014, Current Biology.

[29]  Claudia Bank,et al.  A systematic survey of an intragenic epistatic landscape , 2014, bioRxiv.

[30]  John P. Barton,et al.  The Fitness Landscape of HIV-1 Gag: Advanced Modeling Approaches and Validation of Model Predictions by In Vitro Testing , 2014, PLoS Comput. Biol..

[31]  M. Parera,et al.  Strong epistatic interactions within a single protein. , 2014, Molecular biology and evolution.

[32]  Cécile Viboud,et al.  Spatial Transmission of 2009 Pandemic Influenza in the US , 2014, PLoS Comput. Biol..

[33]  Joshua B. Plotkin,et al.  Contingency and entrenchment in protein evolution under purifying selection , 2014, Proceedings of the National Academy of Sciences.

[34]  R. Sun,et al.  A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity , 2014, PLoS pathogens.

[35]  Andrew L. Ferguson,et al.  Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. , 2013, Immunity.

[36]  M. Wainberg,et al.  Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure , 2013, Retrovirology.

[37]  J. Draghi,et al.  SELECTION BIASES THE PREVALENCE AND TYPE OF EPISTASIS ALONG ADAPTIVE TRAJECTORIES , 2012, Evolution; international journal of organic evolution.

[38]  M. Götte,et al.  The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. , 2012, Current opinion in virology.

[39]  Martin A. Nowak,et al.  Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.

[40]  B. Torbett,et al.  Accessory mutations maintain stability in drug-resistant HIV-1 protease. , 2011, Journal of molecular biology.

[41]  I. Gordo,et al.  Pervasive Sign Epistasis between Conjugative Plasmids and Drug-Resistance Chromosomal Mutations , 2011, PLoS genetics.

[42]  R. Lenski,et al.  Negative Epistasis Between Beneficial Mutations in an Evolving Bacterial Population , 2011, Science.

[43]  S. Borrell,et al.  Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  Sebastian Bonhoeffer,et al.  A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase , 2011, Nature Genetics.

[45]  D. Baker,et al.  Role of conformational sampling in computing mutation‐induced changes in protein structure and stability , 2011, Proteins.

[46]  M. Wainberg,et al.  RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a Protease-Mediated Sequestration of RIG-I , 2010, Journal of Virology.

[47]  R. Shafer,et al.  HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[48]  L. Du,et al.  Global fitness profiling of fission yeast deletion strains by barcode sequencing , 2010, Genome Biology.

[49]  Sebastian Bonhoeffer,et al.  Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations , 2010, Antimicrobial Agents and Chemotherapy.

[50]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[51]  Y. Li,et al.  Prevalent positive epistasis in E. coli and S. cerevisiae metabolic networks , 2009, Nature Genetics.

[52]  A. Camilli,et al.  Tn-seq; high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms , 2009, Nature Methods.

[53]  Bonaventura Clotet,et al.  Epistasis among deleterious mutations in the HIV-1 protease. , 2009, Journal of molecular biology.

[54]  A. Sousa,et al.  Positive Epistasis Drives the Acquisition of Multidrug Resistance , 2009, PLoS genetics.

[55]  H. Kräusslich,et al.  Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss , 2009, PLoS pathogens.

[56]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[57]  Zhijian Lu Second generation HIV protease inhibitors against resistant virus , 2008, Expert opinion on drug discovery.

[58]  David Heckerman,et al.  Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients , 2008, The Journal of experimental medicine.

[59]  Yves Moreau,et al.  Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response , 2008, Antiviral therapy.

[60]  Tony Vangeneugden,et al.  Resistance profile of darunavir: combined 24-week results from the POWER trials. , 2008, AIDS research and human retroviruses.

[61]  F. Maggiolo,et al.  Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.

[62]  L. Chao,et al.  Understanding the Evolutionary Fate of Finite Populations: The Dynamics of Mutational Effects , 2007, PLoS biology.

[63]  W. Heneine,et al.  The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.

[64]  Dan S. Tawfik,et al.  Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein , 2006, Nature.

[65]  Bonaventura Clotet,et al.  HIV-1 Protease Catalytic Efficiency Effects Caused by Random Single Amino Acid Substitutions , 2006, Molecular biology and evolution.

[66]  R. Shafer Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[67]  C. Petropoulos,et al.  Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. , 2006, AIDS research and human retroviruses.

[68]  Thomas Lengauer,et al.  Improved Prediction of Response to Antiretroviral Combination Therapy using the Genetic Barrier to Drug Resistance , 2006, Antiviral therapy.

[69]  Rebecca Hoh,et al.  Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. , 2005, The Journal of infectious diseases.

[70]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[71]  P. Harrigan,et al.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.

[72]  C. Petropoulos,et al.  Evidence for Positive Epistasis in HIV-1 , 2004, Science.

[73]  D. Roze,et al.  Epistasis in RNA Viruses , 2004, Science.

[74]  Rafael Sanjuán,et al.  The contribution of epistasis to the architecture of fitness in an RNA virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Segal,et al.  Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.

[76]  Matthew J. Gonzales,et al.  Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.

[77]  D. Andersson,et al.  Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. , 2004, Research in microbiology.

[78]  D. Bangsberg,et al.  Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.

[79]  Christopher J. Lee,et al.  Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.

[80]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[81]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[82]  M. Malim,et al.  DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.

[83]  M. Gougeon,et al.  Cell death and immunity: Apoptosis as an HIV strategy to escape immune attack , 2003, Nature Reviews Immunology.

[84]  M. Segal,et al.  Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults , 2002, Journal of Virology.

[85]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[86]  D. Kontoyiannis,et al.  Antifungal drug resistance of pathogenic fungi , 2002, The Lancet.

[87]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[88]  J. E. Hyde,et al.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.

[89]  H. Guyatt Bednet benefits blighted by poor coverage , 2001 .

[90]  M. Johnson,et al.  Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations , 2001, Journal of medical virology.

[91]  A. Velázquez‐Campoy,et al.  The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. , 2001, Archives of biochemistry and biophysics.

[92]  R. Grant,et al.  Impaired replication of protease inhibitor-resistant HIV-1 in human thymus , 2001, Nature Medicine.

[93]  C. Cameron,et al.  RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[95]  Pedro R. Lowenstein,et al.  Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity , 2000, Journal of Virology.

[96]  R. Myers,et al.  HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. , 2000, AIDS research and human retroviruses.

[97]  S. Frost,et al.  Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection , 2000, Journal of Virology.

[98]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[99]  C. Boucher,et al.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.

[100]  Santiago F. Elena,et al.  Little Evidence for Synergism Among Deleterious Mutations in a Nonsegmented RNA Virus , 1999, Journal of Molecular Evolution.

[101]  B. Levin,et al.  The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.

[102]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.

[103]  J. Martinez-Picado,et al.  Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[104]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[105]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[106]  J. Perfect,et al.  Antifungal Resistance Trends Towards the Year 2000 , 1997, Drugs.

[107]  B. Korant,et al.  Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[108]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[109]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[110]  E. D. Weinberger,et al.  Fourier and Taylor series on fitness landscapes , 1991, Biological Cybernetics.

[111]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[112]  D. Liberles,et al.  Evolution in the light of fitness landscape theory. , 2019, Trends in ecology & evolution.

[113]  McKimm,et al.  Resistance of influenza viruses to neuraminidase inhibitors — a review , 2000 .

[114]  J. Perfect,et al.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. , 1997, Drugs.